Silence Therapeutics plc is preparing to disclose topline results from the randomized Phase 2 portion of its SANRECO trial of divesiran in polycythemia vera, putting one of the biotechnology company’s most important wholly owned clinical programmes in front of its first placebo-controlled efficacy test. The Nasdaq-listed company has scheduled a conference call and webcast for August 10, 2026, at 8:00 a.m. EDT to discuss the results, meaning the actual Phase 2 dataset had not yet been disclosed in the announcement issued ahead of the event.
That distinction matters. Silence Therapeutics has already generated encouraging open-label Phase 1 evidence suggesting that divesiran can maintain hematocrit control and substantially reduce the need for phlebotomy in patients with polycythemia vera, including follow-up findings presented at the European Hematology Association 2026 Congress. SANRECO Phase 2 is a considerably more demanding test because the study introduces randomisation, double blinding and placebo control, creating the first opportunity to determine whether the earlier signal separates convincingly from control under a more rigorous trial design.
The clinical question is also becoming more competitive. Polycythemia vera drug development has moved beyond simply asking whether manipulation of iron biology can reduce phlebotomy requirements. Protagonist Therapeutics and Takeda have already reported positive Phase 3 results for rusfertide, an investigational hepcidin mimetic, establishing a substantial late-stage benchmark for therapies designed to control erythrocytosis through iron restriction. Divesiran therefore needs to demonstrate not merely biological activity, but a profile that could justify continued development in a field where another iron-regulating approach is substantially further advanced.
What potentially differentiates Silence Therapeutics is how it reaches that objective. Rather than mimicking hepcidin directly, divesiran is an investigational short interfering RNA therapy designed to silence TMPRSS6, thereby increasing endogenous hepcidin and restricting the iron available for red blood cell production. If the Phase 2 results reproduce the hematocrit control observed in the earlier study while supporting dosing every six or 12 weeks, the programme could establish a distinctive development proposition based on durable RNA interference and comparatively infrequent administration.
Why is the randomized SANRECO Phase 2 readout a much tougher test for divesiran than the earlier data?
SANRECO is a Phase 1/2 multicentre study of divesiran, previously known as SLN124, in adults with polycythemia vera. According to the clinical trial registry, the programme began with an open-label dose-escalation component before moving into the randomized, placebo-controlled and double-blind Phase 2 portion. Across Phase 1 and Phase 2, the registered study enrolment is 69 participants, while Silence Therapeutics previously reported that 48 phlebotomy-dependent patients were enrolled specifically into Phase 2.
The primary Phase 2 endpoint is particularly relevant to the practical management of polycythemia vera. The study is evaluating the proportion of patients receiving divesiran versus placebo who maintain hematocrit below 45% without requiring phlebotomy between weeks 18 and 36. That design makes the forthcoming result more informative than simply showing a laboratory change in iron markers or red blood cell parameters.
Maintaining hematocrit control is central to polycythemia vera management because excessive red blood cell production increases blood viscosity and contributes to thrombotic risk. Phlebotomy remains an established means of bringing hematocrit down, but repeated procedures create a treatment burden and deliberately induce iron restriction. A therapy capable of maintaining the hematocrit target while materially reducing phlebotomy requirements could therefore address an important management problem.
The placebo-controlled design will show whether divesiran can deliver that outcome consistently across a broader population rather than only among patients receiving active treatment in an open-label cohort. With just 48 patients in Phase 2, however, the size of the dataset will also matter when interpreting subgroup findings, safety events and secondary outcomes. A statistically persuasive primary endpoint would substantially strengthen the programme, but SANRECO remains a mid-stage study rather than confirmatory evidence of clinical benefit.
How does divesiran use RNA interference to control iron availability and red blood cell production?
Divesiran represents an unusual approach to treating polycythemia vera because it does not directly target the malignant clone responsible for the disease. Instead, Silence Therapeutics is attempting to control one of its most consequential manifestations by altering iron regulation.
The therapy uses short interfering RNA to target TMPRSS6. TMPRSS6 normally acts as a negative regulator of hepcidin, an important hormone controlling systemic iron availability. By reducing expression of TMPRSS6, divesiran is designed to increase endogenous hepcidin, limiting iron availability to the bone marrow and consequently constraining excessive red blood cell production.
This mechanism helps explain why hematocrit and phlebotomy requirements are central measures in SANRECO. Rather than attempting to eliminate the underlying myeloproliferative clone, the strategy seeks to regulate the raw material needed for erythropoiesis sufficiently to keep hematocrit controlled.
That distinction will remain important even if SANRECO produces strong results. Evidence that divesiran controls hematocrit should not automatically be interpreted as evidence that it modifies the underlying course of polycythemia vera. Demonstrating effects on clonal biology, progression or long-term thrombotic outcomes would require appropriate evidence beyond a Phase 2 trial centred on hematocrit control and phlebotomy avoidance.
The attraction of RNA interference is durability. Silence Therapeutics is studying six-week and 12-week dosing schedules in Phase 2, and the longer interval could become commercially meaningful if efficacy remains consistent through the dosing cycle. Treatment frequency, however, becomes a differentiating feature only if efficacy, tolerability and durability support it.
What did the earlier SANRECO Phase 1 findings suggest before the randomized divesiran test?
Silence Therapeutics has gradually strengthened the clinical rationale for divesiran through follow-up from the Phase 1 SANRECO cohort. At the European Hematology Association 2026 Annual Congress, the company presented follow-up and quality-of-life analyses involving 21 phlebotomy-dependent patients with polycythemia vera.
The company reported durable hematocrit control and substantial reductions in phlebotomy use following infrequent divesiran dosing. It also presented analyses suggesting improvement in polycythemia vera-related symptoms and quality of life. Those findings provided supportive evidence that the pharmacological effect may persist beyond the immediate dosing period, which is particularly relevant to the programme’s infrequent-dosing thesis.
There are nevertheless limits to what those observations can establish. Phase 1 was open label, involved a small patient population and was primarily part of an early clinical programme designed to establish safety, tolerability and pharmacological activity. Improvements observed without a randomized control group cannot establish the magnitude of treatment effect that would be expected against placebo or standard management.
The August 10 Phase 2 disclosure therefore represents a genuine evidence transition for divesiran. A clear separation between the active and placebo arms would make the earlier observations considerably more persuasive. Conversely, weaker-than-anticipated separation would force a reassessment of how reliably the Phase 1 effects translate into a controlled setting.
Can divesiran distinguish itself when rusfertide has already delivered positive Phase 3 PV results?
The competitive context has become considerably tougher for Silence Therapeutics because Protagonist Therapeutics and Takeda have moved rusfertide through Phase 3 development.
Rusfertide takes a different pharmacological route toward a related objective. It is an investigational hepcidin mimetic peptide, whereas divesiran uses RNA interference against TMPRSS6 to increase the patient’s endogenous hepcidin. Both strategies ultimately seek to regulate iron availability and thereby control excessive red blood cell production, making the comparison commercially unavoidable even though the therapies have not been evaluated head to head.
The Phase 3 VERIFY study provides a formidable reference point. In the 293-patient randomized study reported in 2025, 76.9% of patients receiving rusfertide achieved the defined clinical response during weeks 20 through 32, compared with 32.9% receiving placebo. Patients treated with rusfertide also averaged 0.5 phlebotomies through week 32 compared with 1.8 in the placebo group, while 62.6% maintained hematocrit below 45% compared with 14.4% of placebo recipients.
Those percentages should not become a simplistic scorecard for SANRECO. VERIFY and SANRECO differ in study size, treatment regimen, endpoint definitions, assessment periods and development stage. Cross-trial comparisons cannot establish whether divesiran is superior or inferior to rusfertide.
They do, however, raise the threshold for what constitutes strategically interesting Phase 2 evidence. Silence Therapeutics is developing divesiran into a landscape where convincing proof that iron regulation can reduce phlebotomy requirements already exists. Its opportunity is therefore increasingly tied to differentiation, particularly durability and dosing convenience, rather than mechanism alone.
Rusfertide has been administered weekly in its development programme. SANRECO is evaluating divesiran every six weeks and every 12 weeks. If both divesiran schedules deliver meaningful hematocrit control, the longer interval could become an important feature for future development. If efficacy weakens materially with extended dosing, that potential advantage would become less compelling.
Which SANRECO results will matter most beyond whether the primary endpoint is technically met?
The headline question will be whether SANRECO meets its prespecified primary endpoint, but the quality of the result will depend on substantially more than a binary success or failure designation.
The magnitude of separation from placebo will be critical. A statistically significant result based on a modest absolute difference would carry different clinical and development implications from a large and consistent treatment effect. The performance of the six-week and 12-week regimens will be especially informative because it could identify whether Silence Therapeutics can preserve efficacy while extending the interval between injections.
Phlebotomy requirements across the study should provide another practical measure. Avoiding a procedure during a defined endpoint window is meaningful, but the cumulative number of procedures and the consistency of hematocrit control can help show whether patients experience sustained benefit rather than episodic control.
Secondary and exploratory outcomes may add information about symptoms and patient experience, particularly after the quality-of-life signals reported from Phase 1. These results should be interpreted according to whether the analyses were prespecified and statistically powered. A small Phase 2 trial can generate useful supporting signals without necessarily providing definitive evidence for every measured outcome.
Safety will require equally careful examination. Because divesiran manipulates iron availability and erythropoiesis, haemoglobin changes, anaemia and other treatment-emergent adverse events will be important to the overall benefit-risk assessment. Treatment discontinuations, serious adverse events and any relationship between dose intensity and tolerability will help determine which regimen, if either, appears suitable for further development.
Could every-six-week or every-12-week dosing become divesiran’s most important competitive advantage?
The dosing experiment embedded in SANRECO may ultimately be almost as strategically important as demonstrating efficacy itself.
RNA interference therapies can produce pharmacodynamic effects that substantially outlast circulating drug exposure because they interfere with production of a target protein. Silence Therapeutics is attempting to translate that characteristic into infrequent dosing for divesiran, with Phase 2 evaluating both six-week and 12-week schedules.
A 12-week regimen would imply roughly four administrations annually if that schedule were eventually supported through later-stage development and regulatory review. That could create a markedly different treatment proposition from weekly administration, particularly in a chronic condition requiring long-term management.
Convenience alone, however, is unlikely to determine clinical positioning. Physicians will primarily need confidence that hematocrit remains reliably controlled throughout the interval. A longer schedule that allows control to deteriorate toward the end of each dosing period would weaken the practical advantage. The Phase 2 curves over time may therefore prove more informative than a single endpoint percentage.
Long-term tolerability will matter as well. The registry indicates that SANRECO includes extended follow-up, with overall study completion projected much later than the initial Phase 2 efficacy readout. That longer observation should provide additional evidence about repeated administration and persistence of effect, although the August topline results will necessarily represent an earlier snapshot.
What would positive SANRECO results mean for Silence Therapeutics’ broader RNA interference pipeline?
Divesiran is one of several programmes through which Silence Therapeutics is attempting to validate its mRNAi GOLD short interfering RNA platform. The company’s current pipeline also includes cardiovascular and metabolic programmes alongside additional hematology opportunities.
That makes SANRECO important beyond polycythemia vera. Clinical success would provide additional human evidence that the company can use RNA interference to produce a sufficiently durable pharmacological effect against a therapeutically relevant liver-expressed target. It would not validate unrelated programmes automatically, since every target and disease presents different biological and clinical challenges, but it would strengthen the platform’s clinical track record.
Divesiran also remains a wholly owned programme, increasing the strategic significance of successful development for Silence Therapeutics. The company lists additional hematologic conditions as potential areas for the asset, although polycythemia vera is currently the programme generating the most advanced clinical evidence.
A positive Phase 2 result would still leave substantial development work ahead. Silence Therapeutics would need to determine the appropriate dose and regimen, engage regulators over the design of subsequent development and ultimately generate evidence sufficient to support any future marketing application. Manufacturing, commercial strategy and competitive positioning would become increasingly important as the programme advances.
The August 10 readout will determine whether divesiran moves from promising mechanism to credible PV contender
The central attraction of divesiran is now relatively easy to define. Silence Therapeutics has an RNA interference therapy with encouraging early evidence, a biologically coherent mechanism, a clinically relevant Phase 2 endpoint and the possibility of dosing substantially less frequently than another advanced iron-regulating therapy in polycythemia vera.
What SANRECO has not yet established, as of the pre-readout announcement, is whether those advantages survive randomized testing.
That is why the August 10 results carry considerably more weight than another incremental pipeline update. A convincing primary endpoint result accompanied by durable hematocrit control, substantial phlebotomy reduction, acceptable tolerability and competitive performance from the longer dosing interval would give Silence Therapeutics a much stronger basis for advancing divesiran. It could also shift the conversation from whether TMPRSS6 silencing works in polycythemia vera to how an infrequently administered RNA interference therapy might ultimately be positioned within an increasingly competitive field.
The competitive bar is already moving. Rusfertide has generated positive Phase 3 evidence, while established approaches to polycythemia vera management give clinicians multiple factors to consider beyond phlebotomy reduction alone. Divesiran therefore does not need merely to produce a positive Phase 2 headline. The more consequential test is whether SANRECO demonstrates a combination of effect size, durability, dosing convenience and tolerability strong enough to justify a larger late-stage programme.
For now, Silence Therapeutics has announced the timing of the readout, not its outcome. Once the actual topline dataset is released at the August 10 conference call, the primary endpoint numbers, placebo separation, six-week versus 12-week performance and safety findings will determine whether divesiran has crossed that threshold.
